(Q40584073)

English

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

scientific article published on June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside (English)

1 reference

Europe PubMed Central

21 September 2017

Hagop Kantarjian

13

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

21 September 2017

Alessandra Ferrajoli

11

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

21 September 2017

5

object named as

Stefan Faderl

1 reference

Europe PubMed Central

21 September 2017

Srdan Verstovsek

8

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

21 September 2017

William G Wierda

12

object named as

William Wierda

1 reference

Europe PubMed Central

21 September 2017

Jorge Eduardo Cortes

4

object named as

Jorge Cortes

1 reference

Europe PubMed Central

21 September 2017

6

object named as

Susan O'Brien

1 reference

Europe PubMed Central

21 September 2017

9

object named as

Mary Beth Rios

1 reference

Europe PubMed Central

21 September 2017

Guillermo Garcia-Manero

1

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

21 September 2017

Francis J Giles

3

object named as

Francis J Giles

1 reference

Europe PubMed Central

21 September 2017

2

object named as

Moshe Talpaz

1 reference

Europe PubMed Central

21 September 2017

10

object named as

Jianquin Shan

1 reference

Europe PubMed Central

21 September 2017

author name string

Deborah Thomas

7

1 reference

Europe PubMed Central

21 September 2017

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

97

1 reference

Europe PubMed Central

21 September 2017

12

1 reference

Europe PubMed Central

21 September 2017

3010-3016

1 reference

Europe PubMed Central

21 September 2017

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of the major positional isomer of pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11424

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11424

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40584073&oldid=1903248491"